Results 21 to 30 of about 25,809 (264)
Journal of the Formosan Medical Association, 2022 Background: Radium-223 is an alpha-emitting, bone-targeting radiopharmaceutical that confers a survival benefit in patients with confirmed bone-metastatic, castration-resistant prostate cancer with no visceral metastases.
Wei-Chun Weng +3 more
doaj +1 more source
Водное хозяйство России: проблемы, технологии, управление, 2022 Development of novel methods of the radiochemical analysis for natural and artificial radionuclides is one of the most urgent current tasks. Th is work deals with studying of laws of sorption pre/concentration of strontium and radium radionuclides in ...
Vladimir S. Semenishchev +4 more
doaj +1 more source
Cancer Medicine, 2023 Background Radium‐233 dichloride is an alpha emitter that specifically targets bone metastases in prostate cancer. Results of a previously reported phase III randomized trial showed survival benefit for radium‐223 compared to best supportive care in ...
Anniina Hyväkkä +10 more
doaj +1 more source
Frontiers in Oncology, 2022 Radium-223 is commonly used in metastatic prostate cancer, targeting specifically bone metastases. The use of radium-223 remains, however, poorly evaluated in metastatic breast cancer.
Hélène Houssiau +3 more
doaj +1 more source
The problem of skipped generation and subclinical disease in familial breast‐ovarian cancer
Acta Obstetricia et Gynecologica Scandinavica, 1997 Background. The major gene for inherited breast ovarian cancer families shows high penetrance in female carriers. Daughters of living unaffected women in these families are supposed to have a low risk of cancer.
Anne Dørum +4 more
doaj +1 more source
iScience, 2022 Summary: Radium is refocused from the viewpoint of an environmental pollutant and cancer therapy using alpha particles, where it mainly exists as a hydrated ion.
Akiko Yamaguchi +14 more
doaj +1 more source